Advocate Christ Medical Center Extends Leadership in Heart Care with Adoption of Genesis Robotic Technology

ST. LOUIS, May 23, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the first treatment of patients with a newly launched Genesis Robotic Magnetic Navigation (RMN) system at Advocate Christ Medical Center in Chicago, Illinois.

Advocate Christ Medical Center, a part of Advocate Health, is the leading provider of robotic heart rhythm care in the Midwest. Electrophysiologists at the hospital have treated over 2,000 patients using advanced robotic technology. The hospital is now among the first in the world, and the first in Chicago, to offer the Genesis RMN system to patients.

"At Advocate Christ, we take pride in providing the highest quality care," said Dr. Jeffrey Neiger, Cardiac Electrophysiologist at Advocate Christ Medical Center. "For more than a decade, our electrophysiology team has leveraged the precision and safety of robotics when treating our cardiac patients. With the adoption of Genesis, we are extending our commitment to that technological and clinical leadership."

Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

"We are excited to continue our partnership with Advocate Christ in advancing the frontiers of patient care and clinical science in cardiology," said David Fischel, Chairman and CEO of Stereotaxis. "We look forward to working with them in ensuring the best possible heart care is available to the Chicago community."

About Stereotaxis

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.